Autolus Therapeutics ( NASDAQ: AUTL ) is scheduled to announce Q2 earnings results on Thursday, August 8th, before market open. The consensus EPS Estimate is -$0.21 (+19.
2% Y/Y) and the consensus Revenue Estimate is $0.06M. Over the last 1 year, AUTL has beaten EPS estimates 50% of the time and has beaten revenue estimates 0% of the time.
Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. More on Autolus Therapeutics Autolus Therapeutics: Major Inflection Point On The Horizon Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity Autolus Therapeutics Q1 2024 Earnings Preview Seeking Alpha’s Quant Rating on Autolus Therapeutics.
